The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Cora N. Sternberg

FACP, Department of Medical Oncology

San Camillo Forlanini Hospital

Circonvallazione Gianicolense 87

[email]@mclink.it

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • FACP, Department of Medical Oncology, San Camillo Forlanini Hospital, Circonvallazione Gianicolense 87. 2003 - 2010
  • San Camillo Forlanini Hospital, Padiglione Flajani, Italy. 2008 - 2010
  • San Camillo and Forlanini Hospitals, Rome, Italy, and EORTC Data Center, Belgium. 2006
  • Vincenzo Pansadoro Foundation, Italy. 2001 - 2003
  • Vincenzo Pansadoro Foundation, Via Aurelia 559, Rome, 00165 Italy, Italy. 2001 - 2002

References

  1. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Sternberg, C.N., Davis, I.D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., Barrios, C.H., Salman, P., Gladkov, O.A., Kavina, A., Zarbá, J.J., Chen, M., McCann, L., Pandite, L., Roychowdhury, D.F., Hawkins, R.E. J. Clin. Oncol. (2010) [Pubmed]
  2. Novel targeted therapy for advanced renal carcinoma: trials in progress. Calabrò, F., Sternberg, C.N. Curr. Opin. Urol (2010) [Pubmed]
  3. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Sternberg, C.N., Dumez, H., Van Poppel, H., Skoneczna, I., Sella, A., Daugaard, G., Gil, T., Graham, J., Carpentier, P., Calabro, F., Collette, L., Lacombe, D. Ann. Oncol. (2009) [Pubmed]
  4. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. Sternberg, C.N., Petrylak, D.P., Sartor, O., Witjes, J.A., Demkow, T., Ferrero, J.M., Eymard, J.C., Falcon, S., Calabrò, F., James, N., Bodrogi, I., Harper, P., Wirth, M., Berry, W., Petrone, M.E., McKearn, T.J., Noursalehi, M., George, M., Rozencweig, M. J. Clin. Oncol. (2009) [Pubmed]
  5. Expanding the boundaries of clinical practice: building on experience with targeted therapies. Sternberg, C.N. Ann. Oncol. (2009) [Pubmed]
  6. The future of prostate cancer. Sternberg, C.N. BJU Int. (2008) [Pubmed]
  7. Antiangiogenic therapy in renal cell carcinoma: a plethora of choices. Sternberg, C.N. Nature Clinical Practice. Urology (2008) [Pubmed]
  8. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Sternberg, C.N., Donat, S.M., Bellmunt, J., Millikan, R.E., Stadler, W., De Mulder, P., Sherif, A., von der Maase, H., Tsukamoto, T., Soloway, M.S. Urology (2007) [Pubmed]
  9. Molecular pathways and the hope of targeting angiogenesis. Sternberg, C.N. Nature Clinical Practice. Urology (2007) [Pubmed]
  10. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Sternberg, C.N., de Mulder, P., Schornagel, J.H., Theodore, C., Fossa, S.D., van Oosterom, A.T., Witjes, J.A., Spina, M., van Groeningen, C.J., Duclos, B., Roberts, J.T., de Balincourt, C., Collette, L. Eur. J. Cancer (2006) [Pubmed]
  11. Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme. Sternberg, C.N. BJU Int. (2006) [Pubmed]
  12. Adjuvant bicalutamide for early prostate cancer: an update. Sternberg, C.N. Nature Clinical Practice. Urology (2006) [Pubmed]
  13. What has been learned from meta-analyses of neoadjuvant and adjuvant chemotherapy in bladder cancer?. Sternberg, C.N., Collette, L. BJU Int. (2006) [Pubmed]
  14. Chemotherapy for local treatment of bladder cancer. Sternberg, C.N. Semin. Radiat. Oncol (2005) [Pubmed]
  15. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Sternberg, C.N., Whelan, P., Hetherington, J., Paluchowska, B., Slee, P.H., Vekemans, K., Van Erps, P., Theodore, C., Koriakine, O., Oliver, T., Lebwohl, D., Debois, M., Zurlo, A., Collette, L. Oncology (2005) [Pubmed]
  16. Satraplatin in the treatment of hormone-refractory prostate cancer. Sternberg, C.N. BJU Int. (2005) [Pubmed]
  17. Adjuvant chemotherapy for bladder cancer. Sternberg, C.N., Calabró, F. Expert. Rev. Anticancer. Ther (2005) [Pubmed]
  18. Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours. Sternberg, C.N., Reichardt, P., Holland, M. Eur. J. Oncol. Nurs (2004) [Pubmed]
  19. What's new in the treatment of advanced prostate cancer?. Sternberg, C.N. Eur. J. Cancer (2003) [Pubmed]
  20. Can patient selection for bladder preservation be based on response to chemotherapy?. Sternberg, C.N., Pansadoro, V., Calabrò, F., Schnetzer, S., Giannarelli, D., Emiliozzi, P., De Paula, F., Scarpone, P., De Carli, P., Pizzo, M., Platania, A., Amini, M. Cancer (2003) [Pubmed]
  21. Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Sternberg, C.N., Vogelzang, N.J. Crit. Rev. Oncol. Hematol. (2003) [Pubmed]
  22. Current perspectives in muscle invasive bladder cancer. Sternberg, C.N. Eur. J. Cancer (2002) [Pubmed]
  23. Highlights of contemporary issues in the medical management of prostate cancer. Sternberg, C.N. Crit. Rev. Oncol. Hematol. (2002) [Pubmed]
  24. Overview of international collaborative group prostate cancer trials. Sternberg, C.N. Crit. Rev. Oncol. Hematol. (2002) [Pubmed]
  25. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. Sternberg, C.N., de Mulder, P.H., Schornagel, J.H., Théodore, C., Fossa, S.D., van Oosterom, A.T., Witjes, F., Spina, M., van Groeningen, C.J., de Balincourt, C., Collette, L. J. Clin. Oncol. (2001) [Pubmed]
  26. Neo-adjuvant chemotherapy in invasive bladder cancer. Sternberg, C.N., Calabrò, F. World. J. Urol (2001) [Pubmed]
  27. Second-line treatment of advanced transitional cell carcinoma of the urothelial tract. Sternberg, C.N. Curr. Opin. Urol (2001) [Pubmed]
  28. Neoadjuvant chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancer. Sternberg, C.N., Parmar, M.K. J. Clin. Oncol. (2001) [Pubmed]
  29. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Sternberg, C.N., Calabrò, F., Pizzocaro, G., Marini, L., Schnetzer, S., Sella, A. Cancer (2001) [Pubmed]
 
WikiGenes - Universities